Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Adaptive Biotechnologies Corp Logo

Combined Holdings of Adaptive Biotechnologies (ADPT) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
May 31, 2022BUY164.513k0.0488%ARKG
May 27, 2022BUY10.035k0.0031%ARKG
May 26, 2022BUY220.717k0.0673%ARKG
May 25, 2022BUY66.777k0.0205%ARKG
May 24, 2022BUY135.512k0.0394%ARKG

Key Statistics

Upcoming EarningsSee Full Calendar
DateAugust 02, 2022(Est)Revenue
Expected$42.48m
Actual▫️
EPS
Expected-$0.43
Actual▫️
🕵🏼Found In🏷Last Price
ARKG$8.42
⚖️Weighting🧢Market Cap
0.4%$1.20b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
497.75
💳ARK Estimated Cost Average🌏Country
$30.71 - ARKG
🇺🇸United States
🎫ARK Ownership Percent
6.16%
Description
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Website
www.adaptivebiotech.com

Research Notes and Commentary for ADPT